Single gene testing has already been influencing clinical decision-making, such as in assessing breast cancer risk and how long a patient will need to stay on medication. But the whole genome will soon become an integral part of practitioners’ decision-making processes. How will genomics better inform providers on everything from risk and progression of disease, to individual response to treatment? Matt Yuill, M.D., Vice President, Quality and Risk Analytics at Interpreta, addresses this, and how barriers to leveraging genomics are being removed, in his latest article in Health IT Outcomes.

Read the full article here